» Articles » PMID: 35542892

Cost-effectiveness of Oral Pre-exposure Prophylaxis and Expanded Antiretroviral Therapy for Preventing HIV Infections in the Presence of Drug Resistance Among Men Who Have Sex with Men in China: A Mathematical Modelling Study

Overview
Date 2022 May 11
PMID 35542892
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Oral pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) can effectively prevent HIV infections among men who have sex with men (MSM), but the emergence and transmission of HIV drug-resistance (HIVDR) may compromise their benefits. The costs and benefits of expanding PrEP and ART coverage in the presence of HIVDR in China remain unknown.

Methods: We developed a comprehensive dynamic transmission model incorporating the transmitted (TDR) and acquired (ADR) HIV drug resistance. The model was calibrated by the HIV surveillance data from 2009 to 2019 among MSM in Jiangsu Province, China, and validated by the dynamic prevalence of ADR and TDR. We aimed to investigate the impact of eight intervention scenarios (no PrEP, 20%, 50% or 80% of PrEP, without (77% coverage) or with (90% coverage) expanded ART) on the HIV epidemic trend and cost-effectiveness of PrEP over the next 30 years.

Findings: 20% or 50% PrEP + 90% ART would be cost-effective, with an incremental cost-effectiveness ratio (ICER) of 25,417 (95% confidence interval [CI]: 12,390-38,445) or 47,243 (23,756-70,729), and would yield 154,949 (89,662-220,237) or 179,456 (102,570-256,342) incremental quality-adjusted life-years (QALYs) over the next 30 years. No PrEP + 90% ART would yield 125,211 (73,448-176,974) incremental QALYs and be cost-saving. However, 20-80% PrEP + 77% ART and 80% PrEP + 90% ART with ICER of $77,862-$98,338 and $63,332, respectively, and were not cost-effective. A reduction of 64% in the annual cost of oral PrEP would make it highly cost-effective for 50% PrEP + 90% ART.

Interpretation: 20% or 50% PrEP + 90% ART is cost-effective for HIV control in the presence of HIVDR. Expanded ART alone may be the optimal policy under the current limited budgets.

Funding: National Natural Science Foundation of China, the National S&T Major Project Foundation of China.

Citing Articles

Preference for HIV Pre-exposure Prophylaxis Access Among Men who Have Sex With Men in China: A Discrete Choice Experiment.

Huang W, Stegmueller D, Sales J, Mi G, Yu F, Liu Y Open Forum Infect Dis. 2025; 12(1):ofae742.

PMID: 39817034 PMC: 11733822. DOI: 10.1093/ofid/ofae742.


Economic evaluation of short message service intervention for HIV prevention among men who have sex with men in China: a modelling study.

Fan R, Shu J, Huang H, Shi L, Ge Q, Zhuang X BMC Public Health. 2024; 24(1):3553.

PMID: 39707268 PMC: 11662610. DOI: 10.1186/s12889-024-20857-3.


Optimizing health resource allocation for improving timely HIV diagnosis in China.

He S, Dong W, Fairley C, Li Z, Wei Y, Lai H J Int AIDS Soc. 2024; 27(3):e26221.

PMID: 38444111 PMC: 10935715. DOI: 10.1002/jia2.26221.


Willingness to use long-acting injectable PrEP among HIV-negative/unknown men who have sex with men in mainland China: A cross-sectional online survey.

Fu J, Dai Z, Wang H, Si M, Chen X, Wu Y PLoS One. 2023; 18(10):e0293297.

PMID: 37856527 PMC: 10586652. DOI: 10.1371/journal.pone.0293297.


Implementation and resource needs for long-acting PrEP in low- and middle-income countries: a scoping review.

Castor D, Heck C, Quigee D, Telrandhe N, Kui K, Wu J J Int AIDS Soc. 2023; 26 Suppl 2:e26110.

PMID: 37439063 PMC: 10339010. DOI: 10.1002/jia2.26110.


References
1.
Huang X, Hou J, Song A, Liu X, Yang X, Xu J . Efficacy and Safety of Oral TDF-Based Pre-exposure Prophylaxis for Men Who Have Sex With Men: A Systematic Review and Meta-Analysis. Front Pharmacol. 2018; 9:799. PMC: 6131617. DOI: 10.3389/fphar.2018.00799. View

2.
Juusola J, Brandeau M, Owens D, Bendavid E . The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med. 2012; 156(8):541-50. PMC: 3690921. DOI: 10.7326/0003-4819-156-8-201204170-00001. View

3.
Xu J, Tang W, Zhang F, Shang H . PrEP in China: choices are ahead. Lancet HIV. 2019; 7(3):e155-e157. DOI: 10.1016/S2352-3018(19)30293-0. View

4.
Wittkop L, Gunthard H, de Wolf F, Dunn D, Cozzi-Lepri A, De Luca A . Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011; 11(5):363-71. DOI: 10.1016/S1473-3099(11)70032-9. View

5.
Molina J, Charreau I, Spire B, Cotte L, Chas J, Capitant C . Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017; 4(9):e402-e410. DOI: 10.1016/S2352-3018(17)30089-9. View